PaySign Inc Dossier
|
SectorFinancials IndustryTransaction & Payment Processing Services Beta (adjusted)0.84 Intrinsic Value $6.20median of 6 methods · middle span $3-$12based on filings through 30 Jun 2026 Market Price $14.36Price as of 1 Oct 2026 Significantly overvaluedIntrinsic value is 57% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-57%) Data confidence Sign in to view data confidence Market Cap $810.8M Enterprise Value $639.6M Shares Outstanding 64.7M diluted Next Earnings Date10 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Paysign, Inc. (NASDAQ: PAYS) is executing a highly successful strategic pivot, transforming from a pure-play plasma donor compensation card provider into a high-margin, rapidly scaling healthcare fintech leader. The primary growth engine is its Patient Affordability business, which has surpassed plasma donor compensation to become the company's largest revenue contributor. This shift is driving significant operating leverage, with Q1 2026 operating margins expanding by over 1,000 basis points to 23.8%. Backed by a capital-light business model, zero bank debt, and a robust cash position, Paysign is uniquely positioned to capture market share across both its core verticals while delivering exceptional top- and bottom-line growth. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$8.50 Mean target$9.95 High · most bullish analyst$12.75 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $8.5020% Growth in the Patient Affordability segment slows due to increased competition or regulatory changes in pharmaceutical co-pay assistance programs. Plasma donor volumes normalize downward, reducing transaction fees. Operating expenses rise due to aggressive hiring and technology investments, compressing margins below guidance. Base CaseCentral scenario $9.9550% Matches the consensus meanPaysign achieves the upper end of its FY 2026 guidance, delivering revenue of $110.5 million (35% YoY growth) and net income of $16.0 million. The Patient Affordability segment maintains steady growth, exiting the year with approximately 155 active programs, while the plasma business continues its stable, recurring performance with moderate center additions. Bull CaseUpside scenario $12.7530% The Patient Affordability segment continues to scale rapidly, exceeding 160 active programs by the end of 2026. Operating leverage expands faster than anticipated, pushing full-year operating margins above 25% and Adjusted EBITDA margins toward 35%. The newly launched Apherion SaaS platform gains rapid adoption among global plasma collectors, creating a high-margin recurring software revenue stream. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |